Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes
暂无分享,去创建一个
[1] G. Lu,et al. Assessing Evidence Inconsistency in Mixed Treatment Comparisons , 2006 .
[2] Paul Landais,et al. Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. , 2004, Journal of clinical epidemiology.
[3] J. Dunn,et al. Prospective Randomized Comparison of Dacarbazine (DTIC) Versus DTIC Plus Interferon-Alpha (IFN-α) in Metastatic Melanoma , 2001 .
[4] A. Brennan,et al. PAR15 USING MIXED TREATMENT COMPARISONS AND METAREGRESSION TO PERFORM INDIRECT COMPARISONS TO ESTIMATE THE EFFICACY OF BIOLOGIC TREATMENTS IN RHEUMATOID ARTHRITIS , 2007 .
[5] M. Atkins,et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] T. Lumley. Network meta‐analysis for indirect treatment comparisons , 2002, Statistics in medicine.
[7] N. G. Best,et al. WinBUGS User Manual: Version 1.4 , 2001 .
[8] P. Queirolo,et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Alex J. Sutton,et al. Heterogeneity: Subgroups, Meta-Regression, Bias And Bias-Adjustment , 2011 .
[10] A E Ades,et al. Synthesis of survival and disease progression outcomes for health technology assessment of cancer therapies , 2010, Research Synthesis Methods.
[11] G. Lu,et al. Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.
[12] J. Dunn,et al. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. , 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).
[13] A. Paccagnella,et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients , 2001, Melanoma research.
[14] Joseph C Cappelleri,et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[15] C. Falkson,et al. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Deborah M Caldwell,et al. Simultaneous comparison of multiple treatments: combining direct and indirect evidence , 2005, BMJ : British Medical Journal.
[17] Arthur P. Dempster,et al. The direct use of likelihood for significance testing , 1997, Stat. Comput..
[18] P. Hersey,et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. , 1993, Melanoma research.
[19] Nicholas R Latimer,et al. Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[20] Jeroen P. Jansen,et al. Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes , 2012 .
[21] Georgia Salanti,et al. Directed acyclic graphs can help understand bias in indirect and mixed treatment comparisons. , 2012, Journal of clinical epidemiology.
[22] N. Welton,et al. Addressing between‐study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non‐rheumatic atrial fibrillation , 2009, Statistics in medicine.
[23] David C Hoaglin,et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[24] Julian P T Higgins,et al. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. , 2009, Journal of clinical epidemiology.
[25] M. Weichenthal,et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Z. Philips,et al. Network meta‐analysis of parametric survival curves , 2010, Research synthesis methods.
[27] D. Schadendorf,et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Georgia Salanti,et al. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. , 2011, Journal of clinical epidemiology.
[29] Nicky J Welton,et al. Evaluating novel agent effects in multiple‐treatments meta‐regression , 2010, Statistics in medicine.
[30] C. Begg,et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Bradley P. Carlin,et al. Bayesian measures of model complexity and fit , 2002 .
[32] Nicky J Welton,et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.
[33] J. Jansen. Network meta-analysis of survival data with fractional polynomials , 2011, BMC medical research methodology.
[34] C. Boni,et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. , 1992, The New England journal of medicine.
[35] Jeroen P Jansen,et al. Network meta‐analysis of individual and aggregate level data , 2012, Research synthesis methods.